Endothelial markers in chronic heart failure: Training normalizes exercise-induced vWF release

European Journal of Clinical Investigation

Volumn 34, Issue 9, 2004, Pages 583-589

  Sabelis, L W E ^a   Senden, P J ^b   Fijnheer, R ^a   De Groot, P G ^a   Huisveld, I A ^a   Mosterd, W L ^a   Zonderland, M L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Chronic heart failure; Endothelial markers; Physical exercise training; vWF release

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; COUMARIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; VON WILLEBRAND FACTOR;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDURANCE EXERCISE; EXERCISE; EXERCISE TOLERANCE; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOSTASIS; HUMAN; MALE; MAXIMUM WORKLOAD; NEW YORK HEART ASSOCIATION CLASSIFICATION; OXYGEN CONSUMPTION; PEAK OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN SECRETION; STRENGTH EXERCISE; TRAINING; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASOMOTOR DISORDER; WORKLOAD;

AGED; ENDOTHELIUM, VASCULAR; EXERCISE; EXERCISE THERAPY; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PLASMINOGEN ACTIVATORS; VON WILLEBRAND FACTOR;

EID: 4944260199     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01388.x     Document Type: Article

References (33)

1. Hinsbergh v VWM. The endothelium: vascular control of haemostasis. Eur J Obst Gynecol Repr Biol 2001;95:198-201.
2. Pearson JD. Normal endothelial cell function. Lupus 2000;9:183-8.
3. Davis CJ, Gurbel PA, Gattis WA, Fuzaylov SY, Nair GV, O'Connor CM et al. Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. Im J Cardiol 2000;75:15-21.
4. Gibbs CR, Blann AD, Edmunds E, Watson RDS, Lip GYH. Effects of acute exercise in hemorheological, endothelial, and platelet markers in patients with chronic heart failure in sinus rhythm. Clin Cardiol 2001;24:724-9.
5. Bastard JP, Piéroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 2000;16:192-201.
6. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:660-5.
7. Swan JW, Anker SD, Wallon C, Godsland IF, Clark AL, Leyva F et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997;30:527-32.
8. Kemppainen J, Tsuchida H, Stolen K, Karlsson H, Björnholm M, Heinonen OJ et al. Insulin signalling and resistance in patients with chronic heart failure. J Physiol 2003;550:305-15.
9. Zelis R, Flaim SF. Alterations in vasomotor tone in chronic heart failure. Prog Cardiovasc Dis 1982;24:437-59.
10. McMurray JJV, Ray SG, Abdulla I, Dargie HJ, Morion JJ. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374-9.
11. Krum H, Denver R, Tzanidis A, Martin P. Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure. Heart Fail Rev 2001;6:341-52.
12. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995;75:1282-3.
13. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998;98:2709-15.
14. Maeda S, Tanabe T, Miyauchi T, Otsuki T, Sugawara J, Iemitsu M et al. Aerobic exercise training reduces plasma endothelin-1 concentration in older women. J Appl Physiol 2003;95:336-41.
15. Burg vd PJM, Hospers JE, Mosterd WL, Bouma BN, Huisveld IA. Aging, physical conditioning, and exercise-induced changes in hemostatic factors and reaction products. J Appl Physiol 2000;88:1558-64.
16. Sabelis LWE, Senden PJ, Boekhorst te BCM, Hulzebos HJ, Wiel vd A, Haeften TW et al. Does physical training increase insulin sensitivity in chronic heart failure patients? Cli Sci 2003;106:459-66.
17. Royal Canadian Air Force. 5BX Plan for physical fitness for men, 1988.
18. Meyer K, Samek L, Schwaibold M, Westbrook S, Hajric R, Lehmann M et al. Physical responses to different modes of interval exercise in patients with chronic heart failure-application to exercise training. Eur Heart J 1996;17:1040-7.
19. Schüler NB, Acquatella H, Ports TA, Drew D, Goerke J, Ringertz H et al. Left ventricular Volume from paired biplane two-dimensional echocardiography. Circulation 1979;60:547-55.
20. Durnin JVGA, Womersley L. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974;32:77-97.
21. Mosnier LO, Borne vd PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998;80:829-35.
22. Hamer RJ, Koedam JA, Beeser-Visser NH, Sixma JJ. Human factor VIII. purification from commercial factor VIII concentrate, characterization, identification and radiolabeling. Biochim Biophys Acta 1986;873:356-66.
23. Gibbs CR, Blann AD, Watson RDS, Lip GYH. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm. Effects of angiotensin-converting enzyme inhibitor and β-blocker therapy. Circulation 2001;103:1746-51.
24. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002;88:1020-5.
25. van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen PJJ et al. von willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999;94:179-85.
26. Lip GYH, Blann AD. von Willebrandfactor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34:255-65.
27. Galbusera M, Zoja C, Donadelli R, Paris S, Morigi M, Benigni A et al. Fluid shear stress modulates von Willebrand Factor release from human vascular endothelium. Blood 1997;90:1558-64.
28. Notarius CF, Ando S, Rongen GA, Floras JS. Resting muscle sympathetic nerve activity and peak oxygen uptake in heart failure and normal subjects. Eur Heart J 1999;20:880-7.
29. Drexler H, Riede U, Mnzler T, König H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation 1992;85:1751-9.
30. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS et al Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A sub-study of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-9.
31. van Mourik JA, Romani de Wit T, Voorberg J. Biogenesis and exocytosis of Weibel-Palade bodies. Histochem Cell Biol 2002;117:113-22.
32. Kinugawa T, Kato M, Ogino K, Osaki S, Igawa O, Hisatome I et al. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. J Card Fail 2003;9:318-24.
33. Hambrecht R, Fiehn E, Yu J, Niebauer J, Weigl C, Hinsbergh v VWM et al. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol 1997;29:1067-73.